|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MFHAS1 |
Gene summary for MFHAS1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MFHAS1 | Gene ID | 9258 |
| Gene name | multifunctional ROCO family signaling regulator 1 | |
| Gene Alias | LRRC65 | |
| Cytomap | 8p23.1 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q9Y4C4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9258 | MFHAS1 | P40T-E | Human | Esophagus | ESCC | 3.27e-02 | 1.01e-01 | 0.109 |
| 9258 | MFHAS1 | P42T-E | Human | Esophagus | ESCC | 3.63e-14 | 9.80e-02 | 0.1175 |
| 9258 | MFHAS1 | P47T-E | Human | Esophagus | ESCC | 2.82e-08 | 2.29e-01 | 0.1067 |
| 9258 | MFHAS1 | P48T-E | Human | Esophagus | ESCC | 1.10e-09 | 2.55e-01 | 0.0959 |
| 9258 | MFHAS1 | P52T-E | Human | Esophagus | ESCC | 1.18e-03 | 2.31e-01 | 0.1555 |
| 9258 | MFHAS1 | P54T-E | Human | Esophagus | ESCC | 4.48e-11 | 4.62e-01 | 0.0975 |
| 9258 | MFHAS1 | P57T-E | Human | Esophagus | ESCC | 3.39e-11 | 1.83e-02 | 0.0926 |
| 9258 | MFHAS1 | P61T-E | Human | Esophagus | ESCC | 1.81e-02 | 2.11e-01 | 0.099 |
| 9258 | MFHAS1 | P62T-E | Human | Esophagus | ESCC | 3.61e-15 | 5.08e-01 | 0.1302 |
| 9258 | MFHAS1 | P74T-E | Human | Esophagus | ESCC | 2.78e-12 | 1.34e-01 | 0.1479 |
| 9258 | MFHAS1 | P75T-E | Human | Esophagus | ESCC | 7.27e-09 | -6.53e-03 | 0.1125 |
| 9258 | MFHAS1 | P76T-E | Human | Esophagus | ESCC | 3.75e-10 | -2.26e-02 | 0.1207 |
| 9258 | MFHAS1 | P79T-E | Human | Esophagus | ESCC | 4.03e-06 | -1.01e-02 | 0.1154 |
| 9258 | MFHAS1 | P80T-E | Human | Esophagus | ESCC | 6.72e-04 | 2.49e-01 | 0.155 |
| 9258 | MFHAS1 | P83T-E | Human | Esophagus | ESCC | 2.24e-14 | 5.74e-01 | 0.1738 |
| 9258 | MFHAS1 | P91T-E | Human | Esophagus | ESCC | 6.35e-08 | 5.87e-01 | 0.1828 |
| 9258 | MFHAS1 | P107T-E | Human | Esophagus | ESCC | 5.25e-12 | 2.80e-01 | 0.171 |
| 9258 | MFHAS1 | P127T-E | Human | Esophagus | ESCC | 4.18e-12 | 7.59e-02 | 0.0826 |
| 9258 | MFHAS1 | P128T-E | Human | Esophagus | ESCC | 4.84e-04 | 4.84e-01 | 0.1241 |
| 9258 | MFHAS1 | P130T-E | Human | Esophagus | ESCC | 7.05e-11 | 1.86e-01 | 0.1676 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00345048 | Cervix | CC | protein localization to nucleus | 68/2311 | 290/18723 | 9.91e-08 | 5.25e-06 | 68 |
| GO:003009910 | Cervix | CC | myeloid cell differentiation | 83/2311 | 381/18723 | 1.31e-07 | 6.42e-06 | 83 |
| GO:00027644 | Cervix | CC | immune response-regulating signaling pathway | 97/2311 | 468/18723 | 1.49e-07 | 7.07e-06 | 97 |
| GO:000226210 | Cervix | CC | myeloid cell homeostasis | 43/2311 | 157/18723 | 2.66e-07 | 1.12e-05 | 43 |
| GO:003410110 | Cervix | CC | erythrocyte homeostasis | 37/2311 | 129/18723 | 5.16e-07 | 1.93e-05 | 37 |
| GO:00310988 | Cervix | CC | stress-activated protein kinase signaling cascade | 58/2311 | 247/18723 | 8.02e-07 | 2.89e-05 | 58 |
| GO:003021810 | Cervix | CC | erythrocyte differentiation | 34/2311 | 120/18723 | 2.00e-06 | 6.18e-05 | 34 |
| GO:004887210 | Cervix | CC | homeostasis of number of cells | 61/2311 | 272/18723 | 2.17e-06 | 6.55e-05 | 61 |
| GO:004593610 | Cervix | CC | negative regulation of phosphate metabolic process | 88/2311 | 441/18723 | 2.92e-06 | 8.27e-05 | 88 |
| GO:00514038 | Cervix | CC | stress-activated MAPK cascade | 55/2311 | 239/18723 | 2.96e-06 | 8.31e-05 | 55 |
| GO:001056310 | Cervix | CC | negative regulation of phosphorus metabolic process | 88/2311 | 442/18723 | 3.21e-06 | 8.77e-05 | 88 |
| GO:00703027 | Cervix | CC | regulation of stress-activated protein kinase signaling cascade | 46/2311 | 195/18723 | 9.35e-06 | 2.11e-04 | 46 |
| GO:00064708 | Cervix | CC | protein dephosphorylation | 60/2311 | 281/18723 | 1.33e-05 | 2.68e-04 | 60 |
| GO:00434104 | Cervix | CC | positive regulation of MAPK cascade | 90/2311 | 480/18723 | 2.92e-05 | 4.83e-04 | 90 |
| GO:00328727 | Cervix | CC | regulation of stress-activated MAPK cascade | 44/2311 | 192/18723 | 3.09e-05 | 5.10e-04 | 44 |
| GO:00507273 | Cervix | CC | regulation of inflammatory response | 75/2311 | 386/18723 | 3.95e-05 | 6.18e-04 | 75 |
| GO:00022212 | Cervix | CC | pattern recognition receptor signaling pathway | 39/2311 | 172/18723 | 1.08e-04 | 1.38e-03 | 39 |
| GO:00622073 | Cervix | CC | regulation of pattern recognition receptor signaling pathway | 27/2311 | 105/18723 | 1.37e-04 | 1.68e-03 | 27 |
| GO:003530310 | Cervix | CC | regulation of dephosphorylation | 31/2311 | 128/18723 | 1.52e-04 | 1.83e-03 | 31 |
| GO:003530410 | Cervix | CC | regulation of protein dephosphorylation | 24/2311 | 90/18723 | 1.73e-04 | 2.04e-03 | 24 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MFHAS1 | SNV | Missense_Mutation | rs750288592 | c.2693N>G | p.Tyr898Cys | p.Y898C | Q9Y4C4 | protein_coding | deleterious(0) | possibly_damaging(0.781) | TCGA-AO-A1KT-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | fluorouracil | SD |
| MFHAS1 | SNV | Missense_Mutation | c.1473N>A | p.Phe491Leu | p.F491L | Q9Y4C4 | protein_coding | deleterious(0.01) | probably_damaging(0.985) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD | |
| MFHAS1 | SNV | Missense_Mutation | c.2573N>A | p.Val858Glu | p.V858E | Q9Y4C4 | protein_coding | tolerated(0.2) | benign(0.005) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| MFHAS1 | insertion | In_Frame_Ins | novel | c.1941_1942insACTCAGACTTCCAAAATGGGTTCCAGT | p.Glu647_His648insThrGlnThrSerLysMetGlySerSer | p.E647_H648insTQTSKMGSS | Q9Y4C4 | protein_coding | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD | ||
| MFHAS1 | SNV | Missense_Mutation | c.1453N>A | p.Glu485Lys | p.E485K | Q9Y4C4 | protein_coding | tolerated(0.08) | benign(0.013) | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| MFHAS1 | SNV | Missense_Mutation | rs780991918 | c.2756N>G | p.Tyr919Cys | p.Y919C | Q9Y4C4 | protein_coding | tolerated(0.08) | benign(0.012) | TCGA-AA-3679-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folinic | SD |
| MFHAS1 | SNV | Missense_Mutation | c.1898G>A | p.Arg633His | p.R633H | Q9Y4C4 | protein_coding | tolerated(0.55) | benign(0.001) | TCGA-AA-3845-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| MFHAS1 | SNV | Missense_Mutation | c.2740T>C | p.Phe914Leu | p.F914L | Q9Y4C4 | protein_coding | tolerated(0.64) | benign(0) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| MFHAS1 | SNV | Missense_Mutation | c.1589C>T | p.Ala530Val | p.A530V | Q9Y4C4 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| MFHAS1 | SNV | Missense_Mutation | c.1910G>A | p.Arg637His | p.R637H | Q9Y4C4 | protein_coding | tolerated(0.14) | benign(0.011) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |